Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27617/Obesity-Therapeutics-to-2019---Safety-Concerns-Hinder-Drug-Performance-Despite-Large-Market-Opportunity/

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market.

Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, GBI Research expects the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals’ negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity.

Scope

- The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and deals surrounding anti-obesity drugs.
- A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options
- Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug’s expected performance within the forecast period
- Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action
- Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type
- An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes.
- A detailed discussion of the drivers and barriers for this immature market.

Reasons to buy

The report will enhance your decision-making capability by allowing you to - 
- Understand the large number of potential molecular targets for the development of an anti-obesity drug, as well as the strengths, weaknesses, and risks of each drug type
- Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development
- Observe the trends in clinical trial duration and size by Phase, molecule type and mechanism of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and future developmental programs
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market
- Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and in depth details of the highest value deals.

PET Scanner Market in India 2013

Reports Corner

Summary

The healthcare industry in India is progressing considerably and the medical device market is one of the most promising segments in this industry. The growth in the health infrastructure in the country, that is, the rise in the number of hospitals, nursing homes and other medical centers is creating a need for sophisticated devices and equipments which can provide accurate treatment to individuals. The global market for medical devices is also growing rapidly and India has joined the bandwagon of being one of the fastest growing countries in this respect. In such an industry, the market for PET scanners is also showing considerable potential. Although there are very few players in the market, all being big multinationals, there is considerable potential for growth in this market and domestic companies can also enter the market and increase profitability. The growing target base of consumers is expected to boost sales and the market is expected to exhibit steady growth in future.

The report provides a snapshot of the PET scanner market. It begins with an overview of the major macro economic indicators of India which highlights the present economic scenario prevalent in the country. It is followed by the introduction section which briefly discusses the working and uses of PET scanners. The next section is the market overview section which provides an insight into the market and highlights the market size and growth of PET scanners in the country. The market size and growth have been provided both value-wise as well as volume-wise.

This is followed by an analysis of the drivers leading to growth in the market. This includes increasing number of cancer cases, increasing cardiovascular diseases, growth in private hospitals and diagnostic centers, changing demographic structure and increasing healthcare spending. The main challenges to the market include the high costs and operational requirements and lack of insurance coverage for PET scans. A section on the major technological trends in this market has also been included. This includes PET/CT, PET/MR and new PET tracers.

The competitive landscape section provides an overview of the competitive scenario in the industry and includes a detailed profile of the major players in the market. The Porter’s Five Forces analysis for the market is provided in this section. It also includes competitive benchmarking of the top players operating in the PET scanner market in India. The report also provides brief profiles of the major domestic and foreign players in the market and a snapshot of their financial performance along with their key financial ratios, business highlights, their product portfolio and SWOT analysis.
A section providing strategic recommendations has been added at the end of the report which gives effective solutions to existing and potential players for improving their market share and increasing their profitability.

Companies Covered
Private
1. Siemens Ltd.
2. GE Healthcare Pvt. Ltd.
3. Philips Electronics India Ltd.

Please visit https://www.reportscorner.com/report_detail.php?r_id=10370 for details.

Search Refurbished Imaging Medical Equipment Market in India 2013

Reports Corner

Summary

Refurbished Imaging Medical Equipment market has witnessed a healthy growth in the recent past and will continue to do so in coming years. Lower cost of refurbished equipments and increasing occurrence of lifestyle diseases are the major drivers for the growth of refurbished imaging equipments.
The report begins with macro economic indicators whereby the basic economic indicators have been depicted. In the introduction section market size of medical equipments in India has been estimated. It also gives the segmentation of the medical equipment market. The introduction section clearly shows both medical equipment markets in general and imaging equipment market in particular is poised to grow at a healthy rate. In the market overview section an overview of the refurbished medical equipments has been provided. A flowchart has been provided to explain how refurbished equipments are bought by hospitals. It also enumerates the checklist for refurbished equipments. Further, the report highlights the different types of ways equipments are refurbished. Thereafter, factors which affect the purchase of refurbished equipment have been listed. Also sourcing of refurbished equipments has been explained. The market overview section also explains the factors which sellers must emphasize on while selling refurbished equipments. Thereafter, the various strategies adopted by refurbished equipment sellers have been explained. Subsequently markets size of refurbished medical equipment such as MRI, CT, X ray, USG and mammography is provided (both in value terms and volume wise). The market for each of these equipments has been explained along with necessary insights and value additions.


In the next section market characteristics of refurbished imaging medical equipments has been listed. This section explains how refurbished equipments lead to quick return on investments. At the same time doctors express serious concern over quality of refurbished equipments which might affect the treatment quality. Patients might be adversely affected.   Sometimes refurbished equipments suffer from poor after sales service resulting in disruption of services.  Rapid technology up-gradation has also resulted in the growth of refurbished equipments in India. Hospitals prefer to buy refurbished equipment as they get a relatively new machine at a fraction of the price. Moreover people are sometimes unaware whether the device is new or refurbished and they are driven only by price-has also resulted in the growth of refurbished imaging medical equipment.
The competition section begins with a Porter’s five forces model which analyses the dynamics of the market. The major players in the market have been profiled which includes a financial summary for each of the players. Key ratios and key contacts are also listed. The last section offers strategic recommendations for the players in the refurbished imaging medical equipment market. For each of the companies a SWOT analysis has been provided.

Companies covered
Public
1. Siemens Ltd.

Private
1. GE Healthcare Pvt. Ltd.
2. Masters Medical Equipments Pvt. Ltd.
3. Sanrad medical Systems
4. Philips Electronics India Ltd.
5. Zigma Meditech India Pvt. Ltd.

Please visit https://www.reportscorner.com/report_detail.php?r_id=10371 for further details.